3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
2
Pancreatic Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Melanoma
1
Locally Advanced Rectal Adenocarcinoma
1
Locally Advanced Cervical Carcinoma
1
Liver Neoplasms
1
Liver Diseases
1
Head and Neck Neoplasms
1
Gastric Cancer With Liver Metastases
1
Esophageal Neoplasms
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Breast Neoplasms
1
Adenocarcinoma
1
Interventions
Specimen Handling
7
Magnetic Resonance Spectroscopy
7
Cisplatin
6
pembrolizumab
4
durvalumab
4
Platinum
4
Carboplatin
4
1,2-diaminocyclohexaneplatinum II citrate
4
cemiplimab
3
Radiation
3
Paclitaxel
3
Cetuximab
3
Biopsy
3
(225)Ac-DOTA-c(RGDyK)
3
cabozantinib
2
atezolizumab
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Pemetrexed
2
Nivolumab
2
Immunoglobulin G
2
Docetaxel
2
Disulfides
2
ALT-803
2
130-nm albumin-bound paclitaxel
2
zipalertinib
1
repotrectinib
1
poly ICLC
1
ipatasertib
1
fludarabine phosphate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
Immunotherapy
×
30 days
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled